A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Adult Refractory Complex Partial Seizures
Interventions
DRUG

Sabril

Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.

Trial Locations (22)

10087

Columbia University Medical Center, New York

19107

Thomas Jefferson University, Philadelphia

19901

CNMRI, Dover

28207

Neuroscience & Spine Institute, Charlotte

29425

Medical University of South Carolina, Charleston

30309

Peachtree Neurological Clinic, Atlanta

33606

University of South Florida, Tampa

40536

University of Kentucky Lexington, Lexington

53215

Aurora St. Luke's Medical Center, Milwaukee

54308

Aurora BayCare Medical Center, Green Bay

55102

Minnesota Epilepsy Group, PA, Saint Paul

61637

OSF Saint Francis Medical Center, Peoria

70121

Ochsner Clinic Foundation, New Orleans

77030

University of Texas, Houston

78229

University of Texas Health Science Center, San Antonio

79410

Covenant Medical Group, Lubbock

83702

Idaho Comprehensive Epilepsy Center, Boise

94115

California Pacific Medical Center, San Francisco

97239

Oregon Health and Science University, Portland

06520

Yale Medical Center, New Haven

33021-2834

Sunrise Clinical Research Group, Hollywood

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lundbeck LLC

INDUSTRY